Donor leukocyte infusions in acute lymphocytic leukemia
نویسندگان
چکیده
منابع مشابه
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated DLI (UDLI) for the treatment of relapsed disease from the National Marrow Donor Program database. A retrospective analysis was performed to determine response, toxicity, and survival after UDLI and to identify factors a...
متن کاملNonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
Allogeneic stem cell transplantation (allo-SCT) is an effective treatment modality for acute myeloid leukemia (AML) that exerts its therapeutic benefit via a graft versus leukemia effect. Its applicability is limited by toxicity from preconditioning chemoradiation in addition to the threat of graft versus host disease, which precludes many patients with AML from receiving this definitive consol...
متن کاملThe role of microRNA in acute/chronic, myeloid/lymphocytic leukemia
MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...
متن کاملDonor Leukocyte Infusions for Chronic Myeloid Leukemia in Relapse after Allogeneic Bone Marrow Transplantation
Allogeneic bone marrow transplantation (BMT) is the only curative therapy for chronic myeloid leukemia (CML), but relapse occurs in approximately 10% of patients transplanted in chronic phase with non T-cell-depleted marrow.’” The risk of relapse is substantially greater if T-cell depletion of donor marrow is used as prophylaxis against graft-versus-host disease (GVHD), when relapse rates of 50...
متن کاملDonor Leukocyte Infusions for Chronic Myeloid Leukemia in Relapse after Allogeneic Bone Marrow Transplantation
Allogeneic bone marrow transplantation (BMT) is the only curative therapy for chronic myeloid leukemia (CML), but relapse occurs in approximately 10% of patients transplanted in chronic phase with non T-cell-depleted marrow.’” The risk of relapse is substantially greater if T-cell depletion of donor marrow is used as prophylaxis against graft-versus-host disease (GVHD), when relapse rates of 50...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 2000
ISSN: 0268-3369,1476-5365
DOI: 10.1038/sj.bmt.1702555